Economics and capital · Venture capital

Enveda Raises $311 Million For AI Drug Trials

Sep 23, 2026, first seen via TechCrunch AI

Enveda raised $311 million at a $2 billion valuation to advance nature-derived AI drug candidates into clinical trials.

Read the original at techcrunch.comOpens the publisher's site in a new tab

More in Economics and capital

AI IPO Delays Signal Growing Investor CautionSep 22 SB Energy delays IPO amid investor skepticismSep 22 Data-center companies delay IPOs amid public backlashSep 21 SoftBank Launches Bonds To Fund OpenAI InvestmentSep 21 Local Opposition Delays $68 Billion Data Center ProjectsSep 21